Question 1

What are the side effects of CJC-1295?

Accepted Answer

The honest shape of this answer is a list borrowed from a whole family of compounds, not a count for this one. A 2026 review of growth hormone axis peptides records that reported adverse effects span endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. In plainer words: shifts in hormones, swelling, muscle and joint pain, and a sore spot where the needle went in. Those come from doctors writing down what walks into a clinic, pooled across sermorelin, tesamorelin, ipamorelin and both versions of CJC-1295. The one source tied to this compound alone is older and much narrower: in the 2006 trials in healthy adults, no serious adverse reactions were reported. A 2026 critical review of peptide use in sport adds a second list, naming cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability. Neither carries a number beside it, so a reader gets the range of things reported rather than any sense of how often.

Question 2

Is CJC-1295 safe to take?

Accepted Answer

No source among the research behind this page settles that, and the reason is worth more than the answer. Safety is something you measure, rather than something you read off a quiet record. Measuring it takes people given the compound, a group given nothing, and blood tests built to catch what nobody expected. A 2026 review in Sports Medicine says where that work stands for the whole unapproved group: rigorous human safety data are scarce, and there is potential for serious harm to patients. A 2026 structured review names this compound, recording that growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions. A 2026 review of peptides in ageing lands in the same place, finding that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. So the point is not that CJC-1295 looked quiet while people were watched. The watching was short, small, and limited to blood.

Question 3

What are the risks of using CJC-1295?

Accepted Answer

The documented risks fall into three kinds, and only the first of them is about the molecule. The first is what this family of compounds does in a body. A 2026 scoping review covering CJC-1295 and five related compounds records that documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance. The same review notes that some peptides such as MK-677 were associated with significant risks including congestive heart failure. That one belongs to MK-677 rather than to CJC-1295, and sits in the list because the two are sold side by side. The second is the distance between a trial and real use. A 2026 critical review states that most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. The third is supply. The same review records that products are often mislabeled or contaminated, which is a hazard that belongs to a vial rather than to a chain of amino acids.

Question 4

What did the human trials record about harm?

Accepted Answer

Two trials finished and one stopped. The 2006 report describes two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d, run in healthy subjects, ages 21-61 yr. Their entire safety finding is one sentence: no serious adverse reactions were reported. Read what a sentence like that can carry. Two short trials in screened volunteers, measuring hormone levels, will pick up an obvious immediate problem rather than a slow one. A 2026 scoping review puts the wider literature in proportion, finding that human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. The trial that might have produced a longer record did not reach the end. The public registry holds a phase 2 entry, A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, whose recorded status is terminated. A trial that stops publishes no table of adverse events, and the registry states the status rather than the reason.

Question 5

Does CJC-1295 affect blood sugar?

Accepted Answer

Dysglycaemia appears on the family list, and that is the extent of it. A 2026 review groups appetite changes, and dysglycaemia among the endocrine and metabolic disturbances reported with growth hormone axis peptides. Dysglycaemia covers readings above or below the range a laboratory calls ordinary. A 2026 scoping review is more specific about the mechanism people ask about, recording metabolic dysfunction such as insulin resistance among the documented risks for this group of compounds. Insulin resistance means the body needs more insulin to clear the same amount of sugar out of the blood. What neither source supplies is a glucose measurement in anyone given CJC-1295. The 2006 trials tracked growth hormone and IGF-I, which are hormone levels rather than sugar readings, and no trial among the research behind this page reports a glucose figure for this compound. So the concern is mechanical and family-wide, rather than a measured result for this compound.

Question 6

Does CJC-1295 cause water retention?

Accepted Answer

Fluid retention syndromes appear by name among the effects clinicians report for this family of compounds. A 2026 review groups them with musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions, which is the cluster most often described together. Fluid retention is the body holding on to water, so it shows as swelling rather than as a number on a test. What the cited sources do not supply is how many people taking CJC-1295 get it, at what amount it starts, or how long it lasts once it does. A 2026 orthopaedic primer is direct about why those figures are missing, stating that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. That gap is why a symptom list reads stronger than it is. A complaint recorded in a clinic is something that happened to somebody, rather than a rate anyone can apply to themselves.

Question 7

Does CJC-1295 cause joint or muscle pain?

Accepted Answer

Musculoskeletal symptoms (myalgia/arthralgia) sit on the same 2026 list of reported effects, and those two words mean muscle pain and joint pain. They appear often enough in growth hormone axis work to have their own line in a review. The route people point to is the one the compound is built around. A 2026 orthopaedic review describes how growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair, meaning they raise a growth signal that acts on muscle and connective tissue. That is a believable route to aching joints, and it has not been tested as one. The same review records that there is a current lack of clinical trials. So a reader holds a symptom list on one side and a mechanism on the other, which is a reason to expect the complaint rather than evidence of it.

Question 8

What happens at the injection site?

Accepted Answer

Injection-site reactions appear on the 2026 list beside the hormonal and musculoskeletal complaints, which puts them among the things clinicians see rather than among the things a trial counted. There is a second route to a sore injection site here, and it has nothing to do with the molecule. Four Class II recalls of CJC-1295 preparations rest on sterility. One covers CJC-1295 Injectable, 6mg/15mg, pre-filled syringe, withdrawn for Lack of Assurance of Sterility. Another covers CJC-1295 2000 mcg/Ipamorelin 2000 mcg/mL Inj. in 2 mL vial, withdrawn for lack of sterility assurance. A sterility failure is a finding about a filling line, and the place it threatens first is the spot where the needle goes in. A sore injection site from the compound and one from a contaminated vial look the same from the outside, which is the practical point.

Question 9

Is there a cancer concern with CJC-1295?

Accepted Answer

A 2026 review names the worry without endorsing it, listing biologically plausible but unproven mitogenic concerns among the things a clinician should keep in mind. Mitogenic means prompting cells to divide, and the concern follows from raising IGF-I rather than from anything seen in a person. The 2006 trials show the exposure that drives the question. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d, which is a sustained lift rather than a short pulse. Plausible and unproven are both doing work in that phrase. No study among the research behind this page has followed anyone taking CJC-1295 for long enough to count cancers, and a 2026 gerontology review records that non-approved peptides lack long-term safety data and systematic validation. That leaves a mechanism with no outcome attached, which is neither a reassurance nor a finding.

Question 10

How long does it take to feel the effects of CJC-1295?

Accepted Answer

Nothing in the cited literature measures a sensation, so the only timings on record are hormonal ones. After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. That is a blood reading rather than a feeling, and the difference matters to anyone checking their own week against a timeline read somewhere. Sleep, appetite and recovery were not outcomes in either completed trial. Where those descriptions do appear is in a 2016 study of online forums. It reports that the stated reasons for use were weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing, drawn from discussion threads rather than from a trial. That is a record of what people said they wanted, which is evidence about a conversation rather than a compound.

Question 11

Does CJC-1295 with DAC carry different risks?

Accepted Answer

The two versions are tracked separately by the people who study them. A 2026 review lists CJC-1295 with Drug Affinity Complex [DAC] and CJC-1295 without DAC as separate entries in one family. A 2021 anti-doping paper keeps the same split, developing detection methods for sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex. The difference that matters for harm is how long each one keeps working. A 2019 analytical paper reports that CJC-1295-protein conjugates have a much greater half-life compared to the unconjugated peptide and are capable of stimulating GH production for more than six days in humans after a single administration. So an unwanted effect from the version with DAC cannot be called off by skipping the next shot. No source among the research behind this page compares harm between the two versions, and that gap in duration is why the comparison would matter rather than a detail.

Question 12

Who was left out of the human trials?

Accepted Answer

Everyone except screened healthy adults in a narrow age band. The 2006 report gives its population in six words: healthy subjects, ages 21-61 yr, were studied. No source among the research behind this page gives a harm figure for anyone outside that. Women are the clearest gap. A 2016 study of online forums found concerns described relating to female consequences of use given gender variations in growth hormone pulses affecting estimation of dosage, cycling, and long-term consequences. That is women raising a question among themselves because the published work has not taken it up. Younger users are the second gap. A 2026 critical review records that anecdotal reports and widespread promotion on social media suggest growing uptake among recreational gym-goers, including younger individuals, but prevalence studies are lacking. Not being counted and not being harmed are different questions, and only the first of them has an answer.

Question 13

Is CJC-1295 banned in sport?

Accepted Answer

Yes, and the ban covers the class rather than this compound alone. A 2021 method paper opens by stating that the administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Section S2 is the hormone category of that list. A 2010 forensic analysis puts the compound itself under Section S2 of the WADA Prohibited List. Being prohibited and being detectable are separate facts, and for years they came apart. The same 2021 paper records that although there is evidence of their use, based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories. A detection limit is the smallest amount a test can see. That gap has been closing, and the method the paper describes reaches the WADA required performance limit of 1 ng/ml or less. A 2026 structured review adds the practical line for anyone competing, that clinicians caring for athletes must counsel patients regarding uncertain efficacy, product quality, safety risks, and antidoping implications.

Question 14

Can you tell what is actually in a CJC-1295 vial?

Accepted Answer

Not from the outside, and the cited record shows what that means. In 2009, an unknown pharmaceutical preparation was submitted for analysis by liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) at the request of Norwegian police and customs authorities. It took that much machinery to establish that the preparation was found to contain a 29 amino acid peptide with a C-terminal amide function, a sequence consistent with a peptide currently marketed under the name CJC-1295. That is the equipment needed to answer a question a label answers in a line of print. A 2026 critical review describes the supply side plainly, recording that products are often mislabeled or contaminated. Four Class II recalls of CJC-1295 preparations are on the FDA enforcement record, every one of them for sterility rather than for contents. A recall describes a production line under inspection, which is narrower than most readers expect.

CJC-1295 side effects and safety data